Department of Pathobiology, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, ON N1G 2W1 Canada.
Vet Pathol. 2011 Jan;48(1):169-81. doi: 10.1177/0300985810390716. Epub 2010 Dec 15.
Molecular assays are widely used to prognosticate canine cutaneous mast cell tumors (MCT). There is limited information about these prognostic assays used on MCT that arise in the subcutis. The aims of this study were to evaluate the utility of KIT immunohistochemical labeling pattern, c-KIT mutational status (presence of internal tandem duplications in exon 11), and proliferation markers--including mitotic index, Ki67, and argyrophilic nucleolar organizing regions (AgNOR)--as independent prognostic markers for local recurrence and/or metastasis in canine subcutaneous MCT. A case-control design was used to analyze 60 subcutaneous MCT from 60 dogs, consisting of 24 dogs with subsequent local recurrence and 12 dogs with metastasis, as compared to dogs matched by breed, age, and sex with subcutaneous MCT that did not experience these events. Mitotic index, Ki67, the combination of Ki67 and AgNOR, and KIT cellular localization pattern were significantly associated with local recurrence and metastasis, thereby demonstrating their prognostic value for subcutaneous MCT. No internal tandem duplication mutations were detected in exon 11 of c-KIT in any tumors. Because c-KIT mutations have been demonstrated in only 20 to 30% of cutaneous MCT and primarily in tumors of higher grade, the number of subcutaneous MCT analyzed in this study may be insufficient to draw conclusions on the role c-KIT mutations in these tumors.
分子检测广泛用于预测犬皮肤肥大细胞瘤(MCT)。关于这些在皮下发生的 MCT 的预后检测,信息有限。本研究的目的是评估 KIT 免疫组织化学标记模式、c-KIT 突变状态(第 11 外显子内部串联重复)和增殖标志物(包括有丝分裂指数、Ki67 和嗜银核仁形成区(AgNOR))作为犬皮下 MCT 局部复发和/或转移的独立预后标志物的效用。采用病例对照设计分析了 60 只来自 60 只狗的皮下 MCT,包括 24 只随后发生局部复发的狗和 12 只发生转移的狗,与未发生这些事件的、具有相同品种、年龄和性别且患有皮下 MCT 的狗相匹配。有丝分裂指数、Ki67、Ki67 和 AgNOR 的组合以及 KIT 细胞定位模式与局部复发和转移显著相关,从而证明了它们对皮下 MCT 的预后价值。在任何肿瘤中均未检测到 c-KIT 外显子 11 中的内部串联重复突变。由于 c-KIT 突变仅在 20%至 30%的皮肤 MCT 中,并且主要在高级别肿瘤中,因此在本研究中分析的皮下 MCT 数量可能不足以得出 c-KIT 突变在这些肿瘤中作用的结论。